Bristol-Myers Squibb Company, Research and Development, Princeton, New Jersey 08543-4000, USA.
J Med Chem. 2010 Feb 11;53(3):1270-80. doi: 10.1021/jm901551w.
The first stereoselective synthesis of the hexahydroimidazo[1,5b]isoquinoline (HHII) scaffold as a surrogate for the steroidal A-B ring system is described. The structure-activity relationships of the analogs derived from this scaffold show that the basic imidazole moiety is tolerated by the glucocorticoid receptor (GR) in terms of binding affinity, although the partial agonist activity in the transrepressive assays depends on the substitution pattern on the B-ring. More importantly, most compounds in the HHII series bearing a tertiary alcohol moiety on the B-ring are either inactive or significantly less active in inducing GR-mediated transactivation, thus displaying a "dissociated" pharmacology in vitro.
首次立体选择性地合成了六氢咪唑并[1,5b]异喹啉(HHII)支架,作为甾体 A-B 环系统的替代物。该支架衍生的类似物的结构-活性关系表明,尽管在反式抑制测定中部分激动活性取决于 B 环上的取代模式,但碱性咪唑部分在结合亲和力方面被糖皮质激素受体(GR)所耐受。更重要的是,在 HHII 系列中,B 环上带有叔醇部分的大多数化合物在诱导 GR 介导的反式激活方面既无活性或活性显著降低,因此在体外显示出“分离”的药理学。